Literature DB >> 3022379

AIDS in Africa: an epidemiologic paradigm.

T C Quinn, J M Mann, J W Curran, P Piot.   

Abstract

Cases of the acquired immune deficiency syndrome (AIDS) have been reported in countries throughout the world. Initial surveillance studies in Central Africa suggest an annual incidence of AIDS of 550 to 1000 cases per million adults. The male to female ratio of cases is 1:1, with age- and sex-specific rates greater in females less than 30 years of age and greater in males over age 40. Clinically, AIDS in Africans is often characterized by a diarrhea-wasting syndrome, opportunistic infections, such as tuberculosis, cryptococcosis, and cryptosporidiosis, or disseminated Kaposi's sarcoma. From 1 to 18% of healthy blood donors and pregnant women and as many as 27 to 88% of female prostitutes have antibodies to human immunodeficiency virus (HIV). The present annual incidence of infection is approximately 0.75% among the general population of Central and East Africa. The disease is transmitted predominantly by heterosexual activity, parenteral exposure to blood transfusions and unsterilized needles, and perinatally from infected mothers to their newborns, and will continue to spread rapidly where economic and cultural factors favor these modes of transmission. Prevention and control of HIV infection through educational programs and blood bank screening should be an immediate public health priority for all African countries.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3022379     DOI: 10.1126/science.3022379

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  83 in total

Review 1.  Primary prevention and international travel: infections, immunizations, and antimicrobial prophylaxis.

Authors:  G S Ferenchick; D H Havlichek
Journal:  J Gen Intern Med       Date:  1989 May-Jun       Impact factor: 5.128

2.  Sperm-associated retroviruses in the mouse epididymis.

Authors:  A A Kiessling; R C Crowell; R S Connell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  No evidence of HIV-2 infection in subjects at risk for AIDS living in north-east Italy.

Authors:  A Del Mistro; A De Rossi; E Francavilla; M T Sartori; L Chieco-Bianchi
Journal:  Eur J Epidemiol       Date:  1991-11       Impact factor: 8.082

Review 5.  Tropical medicine.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

Review 6.  Response to the AIDS pandemic--a global health model.

Authors:  Peter Piot; Thomas C Quinn
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

7.  Surgery in HIV-1 and HIV-2 antibody positive patients.

Authors:  E B Smith
Journal:  J Natl Med Assoc       Date:  1990-08       Impact factor: 1.798

8.  Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study.

Authors:  J M Orenstein; M S Meltzer; T Phipps; H E Gendelman
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Screening of African sera stored for more than 17 years for HIV antibodies by site-directed serology.

Authors:  F Chiodi; G Biberfeld; E Parks; E Norrby; M Mufson
Journal:  Eur J Epidemiol       Date:  1989-03       Impact factor: 8.082

10.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.

Authors:  M Vanden Haesevelde; J L Decourt; R J De Leys; B Vanderborght; G van der Groen; H van Heuverswijn; E Saman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.